However, recent studies have shown that many cancers are resistant to TRAIL agonists or recombinant TRAIL-activating monoclonal antibodies, leading researchers to focus on combination therapies such as sensitizers for TRAIL-induced apoptosis. This evidence concerns the gene TNFSF10 and cancer.